ERBB2 and breast carcinoma: Additionally, the FASN inhibitor cerulenin exhibits synergistic effects with docetaxel in HER-2-overexpressing and docetaxel-resistant SK-BR-3 cells, suggesting involvement of FASN in HER-2-induced breast cancer (155).